News & Events about Arbutus Biopharma Corporation.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS PR Newswire NEW YORK, May 2, 2023 NEW YORK, May 2, 2023...
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post-AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in preclinical models WARMINSTER, Pa., April...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS PR Newswire NEW YORK, April 26, 2023 NEW YORK, April 26...
Ticker Report
2 months ago
Arbutus Biopharma (NASDAQ:ABUS Get Rating)s stock had its market outperform rating reaffirmed by JMP Securities in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $6.00 target price on the biopharmaceutical companys stock...
Globe Newswire
2 months ago
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (Arbutus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral...